Merck & Company Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: MRK-1 Category:


Merck has been in the news for a number of good reasons. The company carried out its long-anticipated spin-off of Organon and a new management team took over the reins of the company including new CEO Rob Davis, new CFO Caroline Litchfield, and new President of Human Health, Frank Clyburn, and new President of Laboratories, Dean Li. A big recent announcement came in the form of a $1.2 billion deal signed by the company and its co-developer Ridgeback Biotherapeutics for their clinical-stage Covid-19 drug, molnupiravir with the U.S. Government subject to successful Phase 3 trials. The company’s orally administered Covid drug has shown a lot of promise in Phase 2 and the stock price could easily zoom up in September/ October 2021 when its Phase 3 results are out. Its 15-valent pneumococcal conjugate vaccine candidate, V114 also showed positive results in Phase 3 trials catering to pneumococcal vaccine-naïve children. Merck is a hot stock and merits a much more detailed analysis.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $496 annual subscription!